Intrathecal kappa free light chain synthesis is associated with worse prognosis in relapsing-remitting multiple sclerosis

J Neurol. 2023 Oct;270(10):4800-4811. doi: 10.1007/s00415-023-11817-9. Epub 2023 Jun 14.

Abstract

Background: While kappa free light chain (KFLC) index has become a useful diagnostic biomarker in multiple sclerosis (MS), its prognostic properties are less explored. B cells play a crucial role in MS pathogenesis, but the impact from increased intrathecal production of immunoglobulins and KFLC remains to be determined. Recently, it has become evident that insidious worsening is not confined to progressive MS but is also common in relapsing-remitting MS (RRMS), a feature known as progression independent of relapse activity (PIRA).

Methods: We retrospectively identified 131 patients with clinically isolated syndrome or early RRMS who had determined KFLC index as part of their diagnostic workup. Demographic and clinical data were extracted from the Swedish MS registry. Associations of baseline KFLC index with evidence of disease activity (EDA) and PIRA were investigated in multivariable cox proportional hazards regression models.

Results: KFLC index was significantly higher in PIRA (median 148.5, interquartile range [IQR] 106.9-253.5) compared with non-PIRA (78.26, IQR 28.93-186.5, p = 0.009). In a multivariable cox regression model adjusted for confounders, KFLC index emerged as an independent risk factor for PIRA (adjusted hazard ratio [aHR] 1.005, 95% confidence interval [CI] 1.002-1.008, p = 0.002). Dichotomized by the cut-off value KFLC index > 100, patients with KFLC index > 100 had an almost fourfold increase in the risk for developing PIRA. KFLC index was also predictive of evidence of disease activity during follow-up.

Conclusions: Our data indicate that high KFLC index at baseline is predictive of PIRA, EDA-3, and overall worse prognosis in MS.

Keywords: Biomarkers; Cerebrospinal fluid; Kappa free light chain index; Multiple sclerosis; Prognosis.

MeSH terms

  • Biomarkers
  • Humans
  • Immunoglobulin kappa-Chains
  • Multiple Sclerosis* / diagnosis
  • Multiple Sclerosis, Chronic Progressive*
  • Multiple Sclerosis, Relapsing-Remitting* / diagnosis
  • Multiple Sclerosis, Relapsing-Remitting* / epidemiology
  • Prognosis
  • Retrospective Studies

Substances

  • Immunoglobulin kappa-Chains
  • Biomarkers